KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) |
|
|
| Recruiting | 1/2 | 314 | US | KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion | Kineta Inc., Merck Sharp & Dohme LLC | Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer | 06/24 | 12/24 | | |
